6600 Stock Overview
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 6600 from our risk checks.
SciClone Pharmaceuticals (Holdings) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$18.04 |
| 52 Week High | HK$18.28 |
| 52 Week Low | HK$8.75 |
| Beta | 0.82 |
| 1 Month Change | 12.47% |
| 3 Month Change | 52.88% |
| 1 Year Change | 49.83% |
| 3 Year Change | 15.20% |
| 5 Year Change | n/a |
| Change since IPO | -4.04% |
Recent News & Updates
Recent updates
SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings
Apr 02
Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today
Dec 14Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Jun 19SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's
May 31Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Feb 17Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)
Dec 02We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings
Oct 04SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings
Jul 27An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued
Jun 02Shareholder Returns
| 6600 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | 0.9% | -3.8% | -1.9% |
| 1Y | 49.8% | -22.4% | -16.4% |
Return vs Industry: 6600 exceeded the Hong Kong Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: 6600 exceeded the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
| 6600 volatility | |
|---|---|
| 6600 Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 7.4% |
| 10% most volatile stocks in HK Market | 14.8% |
| 10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 6600's share price has been volatile over the past 3 months.
Volatility Over Time: 6600's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 860 | Hong Zhao | www.sciclone.com |
SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company’s proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company’s pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer.
SciClone Pharmaceuticals (Holdings) Limited Fundamentals Summary
| 6600 fundamental statistics | |
|---|---|
| Market cap | HK$11.00b |
| Earnings (TTM) | HK$1.21b |
| Revenue (TTM) | HK$3.41b |
9.1x
P/E Ratio3.2x
P/S RatioIs 6600 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6600 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.16b |
| Cost of Revenue | CN¥799.41m |
| Gross Profit | CN¥2.36b |
| Other Expenses | CN¥1.23b |
| Earnings | CN¥1.12b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.84 |
| Gross Margin | 74.67% |
| Net Profit Margin | 35.55% |
| Debt/Equity Ratio | 0% |
How did 6600 perform over the long term?
See historical performance and comparison